4547:TYO
Kissei Pharmaceutical Co Ltd
၃,၇၁၀.၀၀ JP¥
arrow_upward
+၀.၄၁%(+၁၅.၀၀) 1D
အောက် ၉, GMT+၉ ၁၅:၃၀:၀၀ · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
၃,၇၂၅ JP¥
High
၃,၇၄၅ JP¥
Low
၃,၇၀၅ JP¥
Mkt. cap
ဋေ ၁.၇၃ သ
Avg. vol.
၆.၉၃ သောင်း
Volume
၈.၆၉ သောင်း
Dividend
၃.၂၃%
Quarterly dividend
၃၀ JP¥
Ex-dividend date
၂၀၂၆ စက် ၂၉
P/E ratio
၁၁.၀၀
52-wk high
၅,၀၄၀ JP¥
52-wk low
၃,၅၀၀ JP¥
EPS
၃၃၇ JP¥
Shares outstanding
၄.၆၇ ကုဋေ
No. of employees
၂ ထောင်
Open
၃,၇၂၅ JP¥
High
၃,၇၄၅ JP¥
Low
၃,၇၀၅ JP¥
Mkt. cap
ဋေ ၁.၇၃ သ
Avg. vol.
၆.၉၃ သောင်း
Volume
၈.၆၉ သောင်း
Dividend
၃.၂၃%
Quarterly dividend
၃၀ JP¥
Ex-dividend date
၂၀၂၆ စက် ၂၉
P/E ratio
၁၁.၀၀
52-wk high
၅,၀၄၀ JP¥
52-wk low
၃,၅၀၀ JP¥
EPS
၃၃၇ JP¥
Shares outstanding
၄.၆၇ ကုဋေ
No. of employees
၂ ထောင်
News stories
From web sources and news partners
Simply Wall Street
·
ပြီးခဲ့သည့် ၁၅ မိနစ်
Coinbase Stock and 2 Trading Platforms Facing a CFTC Rule Shift
Investing.com
·
ပြီးခဲ့သည့် ၁၃ မိနစ်
Why ’Net Stocks’ are down sharply this year despite Nasdaq’s gains
Seeking Alpha
·
ပြီးခဲ့သည့် ၁ နာရီ
15 Years In, I've Never Seen The S&P 500 Hide So Much Damage
Yahoo Finance
·
ပြီးခဲ့သည့် ၁၄ နာရီ
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees၁.၇၉ ထောင်
Founded၁၉၄၆ ဩ ၉
HeadquartersMatsumoto, Nagano, ဂျပန်
Sector-
Websitekissei.co.jp